XML 27 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation

12. Stock-based Compensation

Stock-based Compensation Expense

Total stock-based compensation expense recognized was as follows (in thousands):

 

 

 

Three Months Ended March 31,

 

 

 

2025

 

 

2024

 

Research and development

 

$

1,620

 

 

$

2,539

 

General and administrative

 

 

1,560

 

 

 

3,140

 

Total stock-based compensation

 

$

3,180

 

 

$

5,679

 

 

Stock Options

A summary of stock option activity for the three months ended March 31, 2025 is set forth below:

 

 

 

Number of
Shares
Underlying
Outstanding
Options

 

 

Weighted
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term
(in years)

 

 

Aggregate
Intrinsic
Value
(in thousands)

 

Outstanding, December 31, 2024

 

 

14,965,270

 

 

$

3.09

 

 

 

8.1

 

 

$

 

Options granted

 

 

4,604,876

 

 

$

0.89

 

 

 

 

 

 

 

Options exercised

 

 

 

 

$

 

 

 

 

 

 

 

Options forfeited or cancelled

 

 

(1,199,653

)

 

$

2.09

 

 

 

 

 

 

 

Outstanding, March 31, 2025

 

 

18,370,493

 

 

$

2.60

 

 

 

8.4

 

 

$

 

Options exercisable, March 31, 2025

 

 

7,601,615

 

 

$

3.43

 

 

 

7.4

 

 

$

 

Vested and expected to vest, March 31, 2025

 

 

18,370,493

 

 

$

2.60

 

 

 

8.4

 

 

$

 

The assumptions used in the Black-Scholes option-pricing model to calculate stock-based compensation are as follows:

 

 

 

Three Months Ended March 31,

 

 

2025

 

2024

Fair value of common stock

 

$0.76 - $0.90

 

$2.35 - $3.12

Expected term (years)

 

6.0 - 6.1

 

6.0 - 6.1

Volatility

 

88.28% - 88.60%

 

82.15% - 84.06%

Risk free rates

 

4.03% - 4.43%

 

3.93% - 4.27%

Dividend rate

 

0.0%

 

0.0%

Restricted Stock Units (RSUs)

The summary of RSU activity and related information for the three months ended March 31, 2025 is set forth below:

 

 

 

Number of Units Outstanding

 

 

Weighted Average
Grant Date Fair Value

 

Outstanding, December 31, 2024

 

 

719,656

 

 

$

4.40

 

RSUs granted

 

 

552,400

 

 

$

0.90

 

RSUs vested

 

 

(256,913

)

 

$

5.06

 

RSUs forfeited

 

 

(100,895

)

 

$

2.12

 

Outstanding, March 31, 2025

 

 

914,248

 

 

$

2.32

 

Option repricing

On August 8, 2023, the board of directors approved a stock option repricing (the Option Repricing) effective on August 14, 2023 (the Effective Date) in accordance with the terms of the Company’s 2015 Stock Incentive Plan (the 2015 Plan) and Second Amended and Restated 2018 Stock Option and Incentive Plan (the 2018 Plan, and together with the 2015 Plan, the Plans). Pursuant to the Option Repricing, the exercise price of each stock option previously granted under the Plans, totaling 6,431,910 options, was amended to reduce the exercise price of such options to $2.14 per share, the closing price of the Company’s common stock on the Nasdaq Global Market on the Effective Date.

The repriced options otherwise retained their existing terms and conditions as set forth in the Plans and applicable award agreements. The stock option modification resulted in $4.6 million of incremental compensation cost, which was calculated using the Black-Scholes option-pricing model. Of the incremental compensation cost, $0.1 million and $0.8 million was recognized in the three months ended March 31, 2025 and 2024, respectively. The remaining incremental compensation cost of $0.5 million, net of the reversal of expense related to employee terminations prior to August 14, 2024, will be recognized on the straight-line basis over the remaining vesting period of the repriced options. The incremental cost is included in general and administrative expense and research and development expense on the consolidated statements of operations.

Effective August 21, 2024, the board of directors approved a rescission of the Option Repricing for certain non-employee directors of the Company. All of the affected stock options have been reverted to their original exercise price as

established at the time of the grant. The Company will continue to recognize the incremental fair value from the Option Repricing for the impacted options. The compensation expense associated with the Option Repricing for these options was not material.